

## Poznámky a literatura

### Úvod: Proč vám lékaři selhali

1. CUSTOM MARKET INSIGHTS. *U.S. Weight Loss Market 2024-2033* [online]. April 2023 [cit. 2025-06-26]. Dostupné z: <https://www.custommarketinsights.com/report/us-weight-loss-market/>
2. LESLIE, R. S., aj. Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists among Non-Diabetic Obese Commercially Insured Adults. *Prime Therapeutics* [online]. Dostupné z: [https://www.primetherapeutics.com/wp-content/uploads/2024/03/4085-C\\_AMCP\\_SP24\\_GLP-1a-Adherence.pdf](https://www.primetherapeutics.com/wp-content/uploads/2024/03/4085-C_AMCP_SP24_GLP-1a-Adherence.pdf)
3. LINCOFF, A. Michael, aj. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *New England Journal of Medicine*. 2023, roč. 389, č. 24, s. 2221-2232. DOI: 10.1056/NEJMoa2307563.

### Kapitola 1: Proč je „víc se snaž“ špatná lékařská rada

1. YEO, Giles S. H. a Lora K. HEISLER. Unraveling the Brain Regulation of Appetite: Lessons from Genetics. *Nature Neuroscience*. 2012, roč. 15, č. 10, s. 1343-1349. DOI: 10.1038/nn.3211.
2. Upraveno z: MORTON, Gregory J., Thomas H. MEEK a Michael W. SCHWARTZ. Neurobiology of Food Intake in Health and Disease. *Nature Reviews Neuroscience*. 2014, roč. 15, č. 6, s. 367-378. DOI: 10.1038/nrn3745.
3. KIRICHENKO, Tatiana V., aj. The Role of Adipokines in Inflammatory Mechanisms of Obesity. *International Journal of Molecular Sciences*. 2022, roč. 23, č. 23, článek 14982. DOI: 10.3390/ijms232314982.
4. OBRADOVIC, Milan, aj. Leptin and Obesity: Role and Clinical Implication. *Frontiers in Endocrinology*. 2021, roč. 12, článek 585887. DOI: 10.3389/fendo.2021.585887.
5. KARATSOREOS, Ilija N., aj. Food for Thought: Hormonal, Experiential, and Neural Influences on Feeding and Obesity. *Journal of Neuroscience*. 2013, roč. 33, č. 45, s. 17610-17616. DOI: 10.1523/JNEUROSCI.3452-13.2013.

Zde jsou další položky poznámek přeložené podle českých citačních norem (ČSN ISO 690):

6. SUMITHRAN, Priya, aj. Long-Term Persistence of Hormonal Adaptations to Weight Loss. *New England Journal of Medicine*. 2011, roč. 365, č. 17, s. 1597–1604. DOI: 10.1056/NEJMoa1105816.
7. BUSETTO, Luca, aj. Mechanisms of Weight Regain. *European Journal of Internal Medicine*. 2021, roč. 93, s. 3–7. DOI: 10.1016/j.ejim.2021.01.002.
8. FOTHERGILL, Erin, aj. Persistent Metabolic Adaptation 6 Years After „The Biggest Loser“ Competition. *Obesity (Silver Spring, MD)*. 2016, roč. 24, č. 8, s. 1612–1619. DOI: 10.1002/oby.21538.
9. STUNKARD, Albert J., aj. The Body-Mass Index of Twins Who Have Been Reared Apart. *New England Journal of Medicine*. 1990, roč. 322, č. 21, s. 1483–1487. DOI: 10.1056/NEJM199005243222102.
10. STUNKARD, Albert J., aj. An Adoption Study of Human Obesity. *New England Journal of Medicine*. 1986, roč. 314, č. 4, s. 193–198. DOI: 10.1056/NEJM198601233140401.
11. DUIS, Jessica a Merlin G. BUTLER. Syndromic and Nonsyndromic Obesity: Underlying Genetic Causes in Humans. *Advanced Biology*. 2022, roč. 6, č. 10, článek e2101154. DOI: 10.1002/adbi.202101154.
12. HALES, C. M., aj. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. *NCHS Data Brief*. 2020, č. 360. Ogden, Cynthia L., Carroll, Margaret D. Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1960–1962 Through 2007–2008. *Division of Health and Nutrition Examination Surveys*.
13. BLACKBURN, Elizabeth. *The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer*. New York: Hachette, 2017, s. 6.
14. KRAL, John G., aj. Large Maternal Weight Loss from Obesity Surgery Prevents Transmission of Obesity to Children Who Were Followed for 2 to 18 Years. *Pediatrics*. 2006, roč. 118, č. 6, článek e1644–e1649. DOI: 10.1542/peds.2006-1379.
15. WARD, Zachary J., aj. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *New England Journal of Medicine*. 2019, roč. 381, č. 25, s. 2440–2450. DOI: 10.1056/NEJMsa1909301.

## Kapitola 2: Jak GLP-1s obracejí obezitu, ukončují jo-jo diety a chrání před nemocemi

1. ARAÚJO, Joana, aj. Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009–2016. *Metabolic Syndrome and Related Disorders*. 2019, roč. 17, č. 1, s. 46–52. DOI: 10.1089/met.2018.0105.
2. ROSENSTOCK, Julio, aj. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. *Lancet (London, England)*. 2021, roč. 398, č. 10295, s. 143–155. DOI: 10.1016/S0140-6736(21)01324-6.

3. SLOMSKI, Anita. Obesity Is Now the Top Modifiable Dementia Risk Factor in the US. *JAMA*. 2022, roč. 328, č. 1, s. 10. DOI: 10.1001/jama.2022.11058.
4. WANG, William, aj. Associations of Semaglutide with Incidence and Recurrence of Alcohol Use Disorder in Real-World Population. *Nature Communications*. 2024, roč. 15, článek 4548. DOI: 10.1038/s41467-024-48780-6.
5. VAZQUEZ, Jeanna. Clinical Trial Studying Possible New Treatment Option for Patients with NAFLD. *UC San Diego Health*. 23. 8. 2023 [online]. Dostupné z: <https://health.ucsd.edu/news/press-releases/2023-08-23-clinical-trial-studying-possible-new-treatment-option-for-patients-with-nafld/>
6. PERKOVIC, Vlado, aj. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2024, roč. 391, č. 2, s. 109–121. DOI: 10.1056/NEJMoa2403347.
7. MALHOTRA, Atul, aj. Tirzepatide for the Treatment of Obstructive Sleep Apnea: Rationale, Design, and Sample Baseline Characteristics of the SURMOUNT-OSA Phase 3 Trial. *Contemporary Clinical Trials*. 2024, roč. 141, článek 107516. DOI: 10.1016/j.cct.2024.107516.
8. NØRGAARD, C. H., aj. Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia: Data from Pooled Double-Blind Randomized Controlled Trials and Nationwide Disease and Prescription Registers. *Alzheimer's & Dementia*. 2022, roč. 8, č. 1, článek e12268. DOI: 10.1002/trc2.12268.

### Kapitola 3: Jaký je skutečný prožitek s GLP-1s: FAQ

1. JASTREBOFF, Ania M., aj. Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine*. 2022, roč. 387, č. 3, s. 205–216. DOI: 10.1056/NEJMoa2206038. WILDING, John P. H., aj. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*. 2021, roč. 384, č. 11, s. 989–1002. DOI: 10.1056/NEJMoa2032183.
2. DAVIES, Melanie J., aj. Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. *JAMA*. 2015, roč. 314, č. 7, s. 687–699. DOI: 10.1001/jama.2015.9676.
3. JASTREBOFF, Ania M., aj. Tirzepatide Once Weekly for the Treatment of Obesity (viz výše).
4. GARVEY, W. Timothy, aj. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo Controlled, Phase 3 Trial. *Lancet*. 2023, roč. 402, č. 10402, s. 613–626. DOI: 10.1016/S0140-6736(23)01200-X.
5. WILDING, John P. H., aj. Once-Weekly Semaglutide in Adults with Overweight or Obesity (viz výše).
6. DAVIES, Melanie J., aj. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Phase 3 Trial. *Lancet*. 2021, roč. 397, č. 10278, s. 971–984. DOI: 10.1016/S0140-6736(21)00213-0.

Zde je převod do českého citačního stylu (ČSN ISO 690), s mírně formálním tónem:

3. JENSTERLE, Mojca, aj. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. *Advances in Therapy*. 2022, roč. 39, č. 6, s. 2452–2467. DOI: 10.1007/s12325-022-02153-x.  
(pozn.: položky 4–6 v originále představují duplicitní citaci JENSTERLE et al.; neuvádím je znovu)
7. ARONNE, Louis J., aj. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA*. 2024, roč. 331, č. 1, s. 38–48. DOI: 10.1001/jama.2023.24945.
8. DAVIES, Melanie J., aj. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). *Lancet*. 2021, roč. 397, č. 10278, s. 971–984. DOI: 10.1016/S0140-6736(21)00213-0.
9. WHARTON, Sean, aj. Managing the Gastrointestinal Side Effects of GLP-1 Receptor Agonists in Obesity: Recommendations for Clinical Practice. *Postgraduate Medicine*. 2022, roč. 134, č. 1, s. 14–19. DOI: 10.1080/00325481.2021.2002616.
10. WHARTON, Sean, aj. Two-Year Effect of Semaglutide 2.4 mg on Control of Eating in Adults with Overweight/Obesity: STEP 5. *Obesity (Silver Spring, MD)*. 2023, roč. 31, č. 3, s. 703–715. DOI: 10.1002/oby.23673.
11. GARVEY, W. Timothy, aj. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. *Nature Medicine*. 2022, roč. 28, č. 10, s. 2083–2091. DOI: 10.1038/s41591-022-02026-4.
- RYAN, Donna H., aj. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. *Nature Medicine*. 2024, roč. 30, s. 2049–2057. DOI: 10.1038/s41591-024-02996-7.
12. RUBINO, Domenica, aj. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA*. 2021, roč. 325, č. 14, s. 1414–1425. DOI: 10.1001/jama.2021.3224.  
(pozn.: položka 13 je duplicitní citace #12)
14. NUAKO, Akua, aj. Pharmacologic Treatment of Obesity in Reproductive Aged Women. *Current Obstetrics and Gynecology Reports*. 2023, roč. 12, č. 2, s. 138–146. DOI: 10.1007/s13669-023-00350-1.
15. KLEIN, Amy. An Ozempic Baby Boom: Some GLP-1 Users Report Unexpected Pregnancies. *Washington Post*. 5. 4. 2024 [online]. Dostupné z: <https://www.washingtonpost.com/wellness/2024/04/05/ozempic-babies-weight-loss-fertility/>
16. WEINSIER, R. L., aj. Medically Safe Rate of Weight Loss for the Treatment of Obesity: A Guideline Based on Risk of Gallstone Formation. *American Journal of Medicine*. 1995, roč. 98, č. 2, s. 115–117. DOI: 10.1016/S0002-9343(99)80394-5.
17. SON, Sang-Yong, aj. Prevention of Gallstones After Bariatric Surgery Using Ursodeoxycholic Acid: A Narrative Review of Literatures. *Journal of Metabolic and Bariatric Surgery*. 2022, roč. 11, č. 2, s. 30–38. DOI: 10.17476/jmbs.2022.11.2.30.
18. LI, Vicky Ka Ming, aj. Predictors of Gallstone Formation After Bariatric Surgery: A Multivariate Analysis of Risk Factors Comparing Gastric Bypass, Gastric Banding, and Sleeve Gastrectomy. *Surgical Endoscopy*. 2009, roč. 23, č. 7, s. 1640–1644. DOI: 10.1007/s00464-008-0204-6.
19. HE, Liyun, aj. Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis

- of Randomized Clinical Trials. *JAMA Internal Medicine*. 2022, roč. 182, č. 5, s. 513–519. DOI: 10.1001/jamainternmed.2022.0338.
20. CAO, Chuqing, aj. GLP-1 Receptor Agonists and Pancreatic Safety Concerns in Type 2 Diabetic Patients: Data from Cardiovascular Outcome Trials. *Endocrine*. 2020, roč. 68, č. 3, s. 518–525. DOI: 10.1007/s12020-020-02223-6.
  21. DANKNER, Rachel, aj. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients with Type 2 Diabetes. *JAMA Network Open*. 2024, roč. 7, č. 1, článek e2350408. DOI: 10.1001/jamanetworkopen.2023.50408.  
(pozn.: položky 22 a 23 jsou duplicitou citací č. 11 a č. 7)
  24. SODHI, Mohit, aj. Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. *JAMA*. 2023, roč. 330, č. 18, s. 1795–1797. DOI: 10.1001/jama.2023.19574.
  25. WANG, William, aj. Association of Semaglutide with Risk of Suicidal Ideation in a Real-World Cohort. *Nature Medicine*. 2024, roč. 30, č. 1, s. 168–176. DOI: 10.1038/s41591-023-02672-2.

## Kapitola 4: Jste kandidátem na GLP-1?

1. WEN, Chi Pang a kol. „Are Asians at Greater Mortality Risks for Being Overweight Than Caucasians? Redefining Obesity for Asians.“ *Public Health Nutrition*, 2009, roč. 12, č. 4, s. 497–506. DOI: 10.1017/S136898 0008002802.

## Kapitola 5: Základní návyky

1. OMICHINSKI, Linda s Mary Evans Young. *You Count, Calories Don't*. Londýn: Hodder & Stoughton, 1992. (upravené)

## Kapitola 6: Základy stravy

1. REYNOLDS, Matt. What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know. *Wired*, 12. 6. 2023 [online]. Dostupné z: <https://www.wired.com/story/obesity-drugs-researcher-interview-ozempic-wegovy/>. Přístup 18. 6. 2024.
2. SHUKLA, Alpana P., a kol. „Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels.“ *Diabetes Care*, 2015, roč. 38, č. 7, čl. e98–e99. DOI: 10.2337/dc15-0429.
3. CARBONE, John W., a kol. „Recent Advances in the Characterization of Skeletal Muscle and Whole-Body Protein Responses to Dietary Protein and Exercise During Negative Energy Balance.“ *Advances in Nutrition*, 2019, roč. 10, č. 1, s. 70–79. DOI: 10.1093/advances/nmy087.
4. BELZA, Anita, a kol. „Contribution of Gastroenteropancreatic Appetite Hormones to Protein-Induced Satiety.“ *American Journal of Clinical Nutrition*, 2013, roč. 97, č. 5, s. 980–989. DOI: 10.3945/ajcn.112.047563.

5. MOON, Jaecheol a Gwanpyo Koh. „Clinical Evidence and Mechanisms of High-Protein Diet-Induced Weight Loss.“ *Journal of Obesity & Metabolic Syndrome*, 2020, roč. 29, č. 3, s. 166–173. DOI: 10.7570/jomes20028.
6. PAL, Sebely a Vanessa Ellis. „The Acute Effects of Four Protein Meals on Insulin, Glucose, Appetite and Energy Intake in Lean Men.“ *British Journal of Nutrition*, 2010, roč. 104, č. 8, s. 1241–1248. DOI: 10.1017/S0007114510001911.
7. PHILLIPS, Stuart M., a kol. „The Role of Milk- and Soy-Based Protein in Support of Muscle Protein Synthesis and Muscle Protein Accretion in Young and Elderly Persons.“ *Journal of the American College of Nutrition*, 2009, roč. 28, č. 4, s. 343–354. DOI: 10.1080/07315724.2009.10718096.
8. PROKSCH, E., a kol. „Oral Supplementation of Specific Collagen Peptides Has Beneficial Effects on Human Skin Physiology: A Double-Blind, Placebo-Controlled Study.“ *Skin Pharmacology and Physiology*, 2014, roč. 27, č. 1, s. 47–55. DOI: 10.1159/000351376.
9. JENDRICKE, Patrick, a kol. „Specific Collagen Peptides in Combination with Resistance Training Improve Body Composition and Regional Muscle Strength in Premenopausal Women: A Randomized Controlled Trial.“ *Nutrients*, 2019, roč. 11, č. 4, čl. 892. DOI: 10.3390/nu11040892.

## Kapitola 7: Mentální základy

1. HOHAIA, Wiremu, a kol. „Occipital Alpha-Band Brain Waves When the Eyes Are Closed Are Shaped by Ongoing Visual Processes.“ *Scientific Reports*, 2022, roč. 12, čl. 1194. DOI: 10.1038/s41598-022-05289-6.

## Kapitola 9: Získání receptu a jeho proplacení

1. FDA. *Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act—Guidance for Industry*. January 2018 [online]. Dostupné z: <https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf>

## Kapitola 10: Proč kardio může ublížit a co místo něj

1. COX, Carla E. „Role of Physical Activity for Weight Loss and Weight Maintenance.“ *Diabetes Spectrum*, 2017, roč. 30, č. 3, s. 157–160. DOI: 10.2337/ds17-0013.
2. LEVINE, James A. „Nonexercise Activity Thermogenesis (NEAT): Environment and Biology.“ *American Journal of Physiology, Endocrinology and Metabolism*, 2004, roč. 286, č. 5, s. E675–E685. DOI: 10.1152/ajpendo.00562.2003.
3. VON LOEFFELHOLZ, Christian a Andreas L. Birkenfeld. „Non-Exercise Activity Thermogenesis in Human Energy Homeostasis.“ In: FEINGOLD, Kenneth R. a kol., eds. *Endotext*. MDText.com, Inc., 2022.

4. KIM, Bokun, a kol. „Changes in Muscle Strength After Diet-Induced Weight Reduction in Adult Men with Obesity: A Prospective Study.“ *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 2017, roč. 10, s. 187–194. DOI: 10.2147/DMSO.S132707.
5. WANG, Zimian, a kol. „Specific Metabolic Rates of Major Organs and Tissues Across Adulthood: Evaluation by Mechanistic Model of Resting Energy Expenditure.“ *American Journal of Clinical Nutrition*, 2010, roč. 92, č. 6, s. 1369–1377. DOI: 10.3945/ajcn.2010.29885.
6. ZHANG, Xiaoming, a kol. „Association of Sarcopenic Obesity with the Risk of All-Cause Mortality Among Adults Over a Broad Range of Different Settings: A Updated Meta-Analysis.“ *BMC Geriatrics*, 2019, roč. 19, čl. 183. DOI: 10.1186/s12877-019-1195-y.
7. REYNOLDS, Gretchen. The Scientific 7-Minute Workout. *New York Times*, 9. 5. 2013 [online]. Dostupné z: <https://nyti.ms/3s5swHj>. Přístup 21. 6. 2024.
8. MORTON, Robert W., a kol. „Neither Load nor Systemic Hormones Determine Resistance Training-Mediated Hypertrophy or Strength Gains in Resistance-Trained Young Men.“ *Journal of Applied Physiology (Bethesda, MD)*, 2016, roč. 121, č. 1, s. 129–138. DOI: 10.1152/jappphysiol.00154.2016.
9. LONGLAND, Thomas M., a kol. „Higher Compared with Lower Dietary Protein During an Energy Deficit Combined with Intense Exercise Promotes Greater Lean Mass Gain and Fat Mass Loss: A Randomized Trial.“ *American Journal of Clinical Nutrition*, 2016, roč. 103, č. 3, s. 738–746. DOI: 10.3945/ajcn.115.119339.
10. CHRISTOFFERSEN, Berit Østergaard, a kol. „Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss.“ *Obesity (Silver Spring, MD)*, 2022, roč. 30, č. 4, s. 841–857. DOI: 10.1002/oby.23374.
11. BLUNDELL, John, a kol. „Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects with Obesity.“ *Diabetes, Obesity & Metabolism*, 2017, roč. 19, č. 9, s. 1242–1251. DOI: 10.1111/dom.12932.
12. JASTREBOFF, Ania M., a kol. „Tirzepatide Once Weekly for the Treatment of Obesity.“ *New England Journal of Medicine*, 2022, roč. 387, č. 3, s. 205–216. DOI: 10.1056/NEJMoa2206038.
13. KLEM, M. L., a kol. „A Descriptive Study of Individuals Successful at Long-Term Maintenance of Substantial Weight Loss.“ *American Journal of Clinical Nutrition*, 1997, roč. 66, č. 2, s. 239–246. DOI: 10.1093/ajcn/66.2.239.
14. MURPHY, Marie H., a kol. „The Effects of Continuous Compared to Accumulated Exercise on Health: A Meta-Analytic Review.“ *Sports Medicine (Auckland, NZ)*, 2019, roč. 49, č. 10, s. 1585–1607. DOI: 10.1007/s40279-019-01145-2.
15. ENGEROFF, Tobias, a kol. „After Dinner Rest a While, After Supper Walk a Mile? A Systematic Review with Meta-analysis on the Acute Postprandial Glycemic Response to Exercise Before and After Meal Ingestion in Healthy Subjects and Patients with Impaired Glucose Tolerance.“ *Sports Medicine (Auckland, NZ)*, 2023, roč. 53, č. 4, s. 849–869. DOI: 10.1007/s40279-022-01808-7.
16. BURRIDGE, Karlijn, a kol. „Obesity History, Physical Exam, Laboratory, Body Composition, and Energy Expenditure: An Obesity Medicine Association (OMA)

Clinical Practice Statement (CPS) 2022.“ *Obesity Pillars*, 2022, roč. 1, čl. 100007. DOI: 10.1016/j.obpill.2021.100007.

X16. HOLMES, Clifton J. a Susan B. Racette. „The Utility of Body Composition Assessment in Nutrition and Clinical Practice: An Overview of Current Methodology.“ *Nutrients*, 2021, roč. 13, č. 8, čl. 2493. DOI: 10.3390/nu13082493.

X17. SIEDLER, Madelin R., a kol. „Assessing the Reliability and Cross-Sectional and Longitudinal Validity of Fifteen Bioelectrical Impedance Analysis Devices.“ *British Journal of Nutrition*, 2023, roč. 130, č. 5, s. 827–840. DOI: 10.1017/S0007114522003749.

## Kapitola 11: Udržování výsledků po celý život

1. JOSHI, Girish P., a kol. *American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-like Peptide-1 (GLP-1) Receptor Agonists*. American Society of Anesthesiologists, 29. června 2023 [online]. Dostupné z: <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-Preoperative>